<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45105">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01751126</url>
  </required_header>
  <id_info>
    <org_study_id>NVG09B113</org_study_id>
    <nct_id>NCT01751126</nct_id>
  </id_info>
  <brief_title>Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Masked, 3 Parallel Arms, Placebo Controlled Study to Assess the Efficacy and Safety of NOVA22007 1mg/mL (Ciclosporin/Cyclosporine) Eye Drops, Emulsion Administered in Paediatric Patients With Active Severe Vernal Keratoconjunctivitis With Severe Keratitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novagali Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novagali Pharma</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>India: Drugs Controller General of India</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Portugal: National Pharmacy and Medicines Institute</authority>
    <authority>Singapore: Health Sciences Authority</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the efficacy of two different dosing regimen of
      NOVA22007 (1mg/ml ciclosporin/cyclosporine) eye drops, emulsion versus placebo (vehicle of
      the formulation) administered four times a day in patients with severe vernal
      keratoconjunctivitis after 4 months of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Compare the composite efficacy score over 4 months of treatment base on keratitis and need for rescue medication for two different dosing regimens of NOVA22007 versus placebo (vehicle of the formulation).</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of will be assessed monthly through slit lamp examination, BCDVA, IOP and safety through vital signs, AE reporting, CsA blood levels and biological tests.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The main secondary endpoints are the assessment of the corneal keratitis, the use of rescue therapy and the occurrence of ulcer which will be assessed monthly.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Vernal Keratoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Ciclosporin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of ciclosporin (NOVA22007) 1 mg/ml 4 times a day as monotherapy (morning, noon, afternoon and evening).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciclosporin/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of ciclosporin (NOVA22007) 1 mg/ml twice a day and one drop of placebo twice a day (active study treatment morning and evening and placebo noon and afternoon) as monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop of placebo 4 times a day as monotherapy (morning, noon, afternoon and evening).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOVA22007 ''Ciclosporin''</intervention_name>
    <description>Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.</description>
    <arm_group_label>Ciclosporin</arm_group_label>
    <arm_group_label>Ciclosporin/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.</description>
    <arm_group_label>Ciclosporin/Placebo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females from 4 to less than 18 years of age.

          -  History of at least one recurrence of vernal keratoconjunctivitis (VKC) in the past
             year prior to enrolment.

          -  Patients not receiving any treatment for an established and active VKC; or patients
             already receiving treatment for their VKC provided treatment is stopped according to
             the wash-out period specified in the exclusion criteria.

          -  Active severe VKC consistent with grade 3 or 4 of Bonini scale (Bonini 2007) with
             severe keratitis (grade 4 or 5 on the modified Oxford scale).

          -  Mean score of 4 subjective symptoms (photophobia, tearing, itching and mucous
             discharge) ≥ 60 mm using a 100 mm Visual Analogue Scale (where &quot;0&quot; means no symptom
             and &quot;100&quot; means the worst that have been ever experienced).

        Exclusion Criteria:

          -  Any relevant ocular anomaly other than VKC interfering with the ocular surface
             including trauma, post radiation keratitis, severe blepharitis, rosacea, corneal
             ulcer etc.

          -  Abnormal lid anatomy, abnormalities of the nasolacrimal drainage system or blinking
             function in either eye.

          -  Active herpes keratitis or history of ocular herpes.

          -  Active ocular infection (viral, bacterial, fungal, protozoal).

          -  Any ocular diseases other than VKC requiring topical ocular treatment during the
             course of the study.

          -  Contact lenses wear during the study.

          -  Topical and/or systemic use of corticosteroids within one week prior to enrolment.

          -  Topical ciclosporin (e.g. Restasis®), tacrolimus or sirolimus within 90 days prior to
             enrolment.

          -  Scraping of the vernal plaque within one month prior to the Baseline visit.

          -  Ocular surgery within 6 months prior to the Baseline visit (excluding surgical
             treatment of the vernal plaque).

          -  Disease not stabilized within 30 days before the Baseline Visit (e.g., diabetes with
             glycemia out of range, thyroid malfunction, uncontrolled autoimmune disease, current
             systemic infections) or judged by the investigator to be incompatible with the study.

          -  Presence or history of severe systemic allergy.

          -  Any systemic immunosuppressant drugs within 90 days before the Baseline Visit.

          -  Known hypersensitivity to one of the components of the study or procedural
             medications (e.g., fluorescein, etc).

          -  History of malignancy in the last 5 years.

          -  Pregnancy or lactation at the Baseline Visit.

          -  History of ocular varicella-zoster or vaccinia virus infection.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mourad Amrane, MD</last_name>
    <phone>+33 (0)1 69 87 40 20</phone>
    <email>mourad.amrane@novagali.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Glendale, CA, USA</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Irvine, CA, USA</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rancho Cordova, CA, USA</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille, Bouches-du-Rhône, FR</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du-Rhône</state>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Angers CEDEX 9, Maine-et-Loire, FR</name>
      <address>
        <city>Angers CEDEX 9</city>
        <state>Maine-et-Loire</state>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amiens CEDEX, Somme, FR</name>
      <address>
        <city>Amiens CEDEX</city>
        <state>Somme</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tours CEDEX 9, FR</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris CEDEX 8, Île-de-France, FR</name>
      <address>
        <city>Paris CEDEX 8</city>
        <state>Île-de-France</state>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szeged, Csongrád, HU</name>
      <address>
        <city>Szeged</city>
        <state>Csongrád</state>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debrecen, Hajdú-Bihar, HU</name>
      <address>
        <city>Debrecen</city>
        <state>Hajdú-Bihar</state>
        <zip>H-4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Budapest, HU</name>
      <address>
        <city>Budapest</city>
        <zip>H-1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Be'er-Sheva, IL</name>
      <address>
        <city>Be'er-Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jerusalem, IL</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Petah-Tikva, IL</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rehovot, IL</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv, IL</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bologna, Emilia-Romagna, IT</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lavagna, Liguria, IT</name>
      <address>
        <city>Lavagna</city>
        <state>Liguria</state>
        <zip>16033</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Firenze, Tuscany, IT</name>
      <address>
        <city>Firenze</city>
        <state>Tuscany</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Padova, Veneto, IT</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vila Nova de Gaia, Douro Litoral, PT</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <state>Douro Litoral</state>
        <zip>4434-502</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lisboa, Extremadura, PT</name>
      <address>
        <city>Lisboa</city>
        <state>Extremadura</state>
        <zip>1500-473</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lisboa, Extremadura, PT</name>
      <address>
        <city>Lisboa</city>
        <state>Extremadura</state>
        <zip>1169-019</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lisboa, Extremadura, PT</name>
      <address>
        <city>Lisboa</city>
        <state>Extremadura</state>
        <zip>1150-199</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Torrevieja, Alicante, ES</name>
      <address>
        <city>Torrevieja</city>
        <state>Alicante</state>
        <zip>03186</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barakaldo, Biscay, ES</name>
      <address>
        <city>Barakaldo</city>
        <state>Biscay</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Sebastián, Guipúzcoa, ES</name>
      <address>
        <city>San Sebastián</city>
        <state>Guipúzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aranjuez, Madrid, ES</name>
      <address>
        <city>Aranjuez</city>
        <state>Madrid</state>
        <zip>28300</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A Coruña, A Coruña, ES</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alicante, Alicante, ES</name>
      <address>
        <city>Alicante</city>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Madrid, Madrid, ES</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Madrid, Madrid, ES</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sevilla, Sevilla, ES</name>
      <address>
        <city>Sevilla</city>
        <zip>41003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valencia, Valencia, ES</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valencia, Valencia, ES</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 25, 2014</lastchanged_date>
  <firstreceived_date>December 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vernal keratoconjunctivitis</keyword>
  <keyword>ciclosporin</keyword>
  <keyword>cyclosporine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
